Appendix 2.

Reviewer Relationships With Industry and Other Entities—2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)

ReviewerRepresentationConsultantSpeaker's BureauOwnership/Partnership/ PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
John E. BrushOfficial Reviewer–ACCF Board of Trustees
  • United Healthcare

NoneNoneNone
  • PROMETHEUS Payment (Board member)

None
David P. FaxonOfficial Reviewer–AHA
  • Johnson & Johnson

None
  • CULPRIT Trial (PI)*

  • RIVA Medical

None
  • Circulation: Cardiovascular Interventions—Editor*

None
Robert A. HarringtonOfficial Reviewer–AHA
  • AstraZeneca*

  • Baxter

  • CSL Behring

  • Eli Lilly

  • Luitpold

  • The Medicines Company

  • Merck

  • Novartis

  • Otsuka Maryland Research Institute

  • Regado

  • Sanofi-aventis

  • Schering-Plough*

  • WebMD*

NoneNone
  • AstraZeneca

  • Baxter

  • Bristol-Myers Squibb*

  • GlaxoSmithKline

  • The Medicines Company

  • Merck*

  • Portola*

  • Schering-Plough*

NoneNone
Judith S. HochmanOfficial Reviewer–ACCF/AHA Task Force on Practice Guidelines
  • BMS/Sanofi

  • Eli Lilly

  • GlaxoSmithKline

  • Millennium Pharmaceuticals/ Schering-Plough

NoneNone
  • Johnson & Johnson/Bayer Healthcare AG (DSMB)

  • Schering-Plough (TIMI 50) (DSMB)

NoneNone
Rodney H. ZimmermannOfficial Reviewer–ACCF Board of Governors
  • AstraZeneca

  • Boehringer Ingelheim

  • Bristol-Myers Squibb

  • Medtronic

  • Sanofi-aventis

  • Schering-Plough

  • AstraZeneca

  • Merck-Frost

  • Sanofi-aventis

  • Servier

None
  • AstraZeneca

  • Sanofi-aventis

NoneNone
Steven BrownOrganizational Reviewer–AAFPNoneNoneNoneNoneNoneNone
Joseph C. ClevelandOrganizational Reviewer–STS
  • Baxter Biosurgery

  • Essential Pharmaceuticals

NoneNoneNone
  • Heartware

  • Thoratec

None
Wyatt DeckerOrganizational Reviewer–ACEPNoneNoneNoneNoneNoneNone
Joseph A. de GregorioOrganizational Reviewer–SCAINoneNoneNoneNoneNoneNone
Deborah B. DiercksOrganizational Reviewer–ACEP
  • AstraZeneca

  • Sanofi-aventis

  • Schering-Plough

NoneNoneNone
  • Society of Chest Pain Centers and Providers

None
Benjamin HattenOrganizational Reviewer–ACEPNoneNoneNoneNoneNoneNone
Loren F. HiratzkaOrganizational Reviewer–STSNoneNoneNoneNone
  • Cardiac, Vascular, and Thoracic Surgeons*

  • TriHealth (Bethesda North and Good Samaritan Hospitals)*

None
Jason H. RogersOrganizational Reviewer–SCAI
  • Ample Medical

NoneNoneNoneNoneNone
Vincenza T. SnowOrganizational Reviewer–ACPNoneNoneNone
  • Boehringer Ingelheim*

  • Bristol-Myers Squibb*

  • ACP*

None
Elliott M. AntmanContent Reviewer
  • Eli Lilly

  • Momenta Pharmaceuticals

  • Sanofi-aventis

NoneNone
  • Accumetrics

  • Amgen

  • AstraZeneca

  • Bayer Healthcare

  • Beckman Coulter

  • Bristol-Myers Squibb Pharmaceutical Research Institute

  • CV Therapeutics

  • Daiichi Sankyo*

  • Eli Lilly*

  • GlaxoSmithKline

  • NIH

  • Merck

  • Millennium Pharmaceuticals

  • Inotek Pharmaceuticals

  • Integrated Therapeutics

  • Novartis

  • Ortho-Clinical Diagnostics

  • Pfizer

  • Roche Diagnostics

  • Roche Diagnostics GmbH

  • Sanofi-aventis*

  • Sanofi-Synthelabo Recherche

  • Schering-Plough Research Institute

NoneNone
Brian BachelderContent ReviewerNoneNoneNoneNoneNoneNone
James C. BlankenshipContent Reviewer
  • AstraZeneca

  • Boston Scientific

  • Conor Medsystems

  • Kai Pharmaceutical

  • Schering-Plough

NoneNone
  • Abiomed

  • Novartis

NoneNone
James A. BurkeContent Reviewer–ACCF Interventional Scientific CouncilNoneNoneNoneNoneNoneNone
Christopher P. CannonContent Reviewer
  • Bristol-Myers Squibb

NoneNone
  • Accumetrics*

  • AstraZeneca*

  • BMS/Sanofi-aventis*

  • GlaxoSmithKline (DSMB)

  • GlaxoSmithKline

  • Kai Pharmaceuticals (DSMB)

  • Merck (DSMB)

  • Merck*

  • Takeda

None
  • 2009: Defendant, Postoperative Myocardial Infarction

William A. ChaveyContent ReviewerNoneNoneNoneNoneNoneNone
Rienzi A. DiazContent ReviewerNoneNoneNoneNoneNoneNone
T. Bruce FergusonContent Reviewer–ACCF Surgeon's Scientific CouncilNoneNoneNone
  • Novadaq Technologies*

NoneNone
John M. FieldContent ReviewerNoneNoneNoneNoneNoneNone
David F. FortuinContent ReviewerNoneNoneNoneNone
  • Boston Scientific

  • Medtronic

  • Merck

None
Christopher B. GrangerContent Reviewer
  • AstraZeneca

  • Boehringer Ingelheim

  • Gilead Pharmaceutical

  • GlaxoSmithKline

  • Roche

  • Novartis

  • The Medicines Company

  • Sanofi-aventis

NoneNone
  • AstraZeneca

  • Boehringer Ingelheim

  • Bristol-Myers Squibb*

  • DeCode

  • GlaxoSmithKline*

  • The Medicines Company*

  • Sanofi-aventis

NoneNone
Mary HandContent ReviewerNoneNoneNoneNoneNoneNone
P. Michael HoContent Reviewer
  • Wellpoint

NoneNoneNoneNoneNone
Alan S. JaffeContent Reviewer
  • Beckman-Coulter

  • Critical Diagnostics

  • Ortho Diagnostics

  • Pfizer

  • Siemens

  • Tethys Bioscience

NoneNoneNoneNoneNone
Sanjay KaulContent Reviewer
  • Hoffman La Roche

  • Novo Nordisk

NoneNone
  • Hoffman La Roche*

NoneNone
Lloyd W. KleinContent Reviewer–ACCF Interventional Scientific Council
  • Pfizer

  • Daiichi Sankyo/Eli Lilly

NoneNoneNoneNone
Harlan M. KrumholzContent Reviewer
  • United Health (Science Advisory Group)

NoneNoneNoneNoneNone
Frederick G. KushnerContent Reviewer–ACCF/AHA Task Force on Practice GuidelinesNoneNone
  • Hoffman La Roche*

  • Pfizer

None
  • Daiichi Sankyo (Sub-I)

  • Hoffmann La Roche (Sub-I)

  • NIH (Sub-I)

None
Shamir R. MehtaContent Reviewer
  • Astellas

  • AstraZeneca

  • Bristol-Myers Squibb

  • Eli Lilly

  • Sanofi-aventis

NoneNone
  • Bristol-Myers Squibb*

  • Sanofi-aventis*

NoneNone
Douglass A. MorrisonContent ReviewerNoneNoneNoneNoneNoneNone
L. Kristin NewbyContent Reviewer
  • AstraZeneca

  • BG Medicine

NoneNone
  • diaDexus*

  • GlaxoSmithKline*

  • Merck*

  • Schering-Plough*

  • Society of Chest Pain Centers

None
E. Magnus OhmanContent Reviewer–ACCF/AHA Task Force on Practice Guidelines
  • Abiomed*

  • CV Therapeutics

  • Datascope*

  • Gilead Sciences*

  • Liposcience

  • Pozen

  • Response Biomedical

  • Schering-Plough

  • WebMD*

NoneNone
  • Bristol-Myers Squibb*

  • Daiichi Sankyo*

  • Datascope*

  • Eli Lilly*

  • Sanofi-aventis*

  • Schering-Plough*

  • The Medicines Company*

NoneNone
Pamela N. PetersonContent ReviewerNoneNoneNoneNoneNoneNone
William A. Tansey IIIContent ReviewerNoneNoneNoneNoneNoneNone
  • This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

  • * Significant relationship.

  • AAFP indicates American Academy of Family Physicians; ACCF, American College of Cardiology Foundation; ACEP, American College of Emergency Physicians; ACP, American College of Physicians; AHA, American Heart Association; DSMB, data safety monitoring board; NIH, National Institutes of Health; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; Sub-I, subinvestigator; and TIMI, Thrombolysis in Myocardial Infarction.